| Autor: |
Hafez, Wael, Ziade, Mohamad Azzam, Arya, Arun, Saleh, Husam, Abdelshakor, Mahmoud, Fadl Alla, Osman, Agrawal, Pragati, Ali, Sara, Rao, Srinivasa Raghu, Gupta, Subrata, Abdelli, Ikram, Sebastian, Honeymol, Ali, Mohamed, Gador, Muneir, Al Baha, Ziad, Abdelrahman, Ahmed |
| Předmět: |
|
| Zdroj: |
Antibiotics (2079-6382); Feb2022, Vol. 11 Issue 2, p241, 1p |
| Abstrakt: |
(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterized by the release of several immune modulators, including Interleukin-6 (IL-6). Tocilizumab (TCZ) is an IL-6 receptor antagonist used to treat rheumatic arthritis. The study aimed to evaluate the efficacy and safety of TCZ against COVID-19. (2) Methods: This was a retrospective study including 49 severe COVID-19 patients who received TCZ therapy in NMC Royal Hospital, UAE. (3) Results: Before Tocilizumab administration, the median temperature was 37.0 (IQR 36.0–39.6), and after day seven, the median reduced to 36.5 (IQR 35.8–37.9), p > 0.001. Thirty (61.2%) patients were admitted to the ICU, of which, eight (16.3%) were on WHO scale 4, sixteen (32.6%) on scale 5, and six (20.0%) on scale 6. TCZ reduced inflammatory markers over time, including CRP, D-Dimer, Ferritin, and Fibrinogen. By the end of week seven, 14 patients died (28.6%) while 35 (71.4%) improved and were discharged. (4) Conclusions: The study showed limited improvements in COVID-19 outcomes with TCZ therapy and highlighted the importance of D-Dimer monitoring for possible risk of thrombosis. Additionally, it could be recommended to upgrade the anti-coagulation dose to therapeutic levels once TCZ therapy is decided upon. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
